Chemoprevention for brain metastases

Current Oncology Reports

Volumn 14, Issue 1, 2012, Pages 63-69

  Trinh, Van A ^a   Hwu, Wen Jen ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Brain metastases; Breast cancer; Chemoprevention; Lung cancer; Melanoma; Renal cell carcinoma

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; DABRAFENIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOTEMUSTINE; GEFITINIB; IPILIMUMAB; LAPATINIB; LOMUSTINE; METHOTREXATE; NITROSOUREA; PACLITAXEL; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TRASTUZUMAB; VEMURAFENIB;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CDH2 GENE; DRUG PENETRATION; DRUG TARGETING; FALZ GENE; HUMAN; KIDNEY CARCINOMA; KIFC1 GENE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MOLECULARLY TARGETED THERAPY; ONCOGENE; PATHOGENESIS; PROPHYLACTIC CRANIAL IRRADIATION; RISK FACTOR; RISK REDUCTION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; SKIN NEOPLASMS;

EID: 84857632433     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-011-0200-1     Document Type: Article

References (35)

1. JC Bendell SM Domchek HJ Burstein, et al. 2003 Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma Cancer 97 12 2972 2979 12784331 10.1002/cncr.11436 (Pubitemid 36676250)
2. S Paget 1889 The distribution of secondary growth in cancer of the breast Lancet 133 3421 571 573 10.1016/S0140-6736(00)49915-0 Over a century ago in 1889, the "seed and soil" theory was proposed by Stephen Paget to hypothesize what determined which organ should receive disseminated cancer cells. He was convinced that site of secondary growth was not a matter of chance but was the result of favorable interactions between tumor cells (the seeds) and organ microenvironment (the soil)
3. IJ Fidler K Balasubramanian Q Lin SW Kim SJ Kim 2010 The brain microenvironment and cancer metastasis Moll Cells 30 2 93 98 10.1007/s10059-010-0133-9 1:CAS:528:DC%2BC3cXhtVOmt77I The authors apply Paget's "seed and soil" hypothesis to BMs and discuss recent understanding of cerebral neoplastic neovascularization and facilitatory role of astrocytes in the development of BMs, giving hope for new therapeutic approaches to treat this fatal disease
4. AM Chen TM Jahan DM Jablons J Garcia DA Larson 2007 Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain Cancer 109 8 1668 1675 17342770 10.1002/cncr.22565 (Pubitemid 46595704)
5. R Yamanaka 2009 Medical management of brain metastases from lung cancer (review) Oncol Rep 22 6 1269 1276 19885576 10.3892/or-00000564 1:CAS:528:DC%2BD1MXhsFWlu7zL
6. Z Huang C Brdlik P Jin HM Shapard 2009 A pan-HER approach for cancer therapy: background, current status and future development Expert Opin Biol Ther 9 1 97 110 19063696 10.1517/14712590802630427 1:CAS:528:DC%2BD1cXhsVKrs7vJ
7. Y Yatabe T Takahashi T Mitsudomi 2008 Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer Cancer Res 68 7 2106 2111 18381415 10.1158/0008-5472. CAN-07-5211 1:CAS:528:DC%2BD1cXktVyqtbk%3D (Pubitemid 351521782)
8. PA Bunn Jr R Dziadziusko M Varella-Garcia WA Franklin SE Witta K Kelly FR Hirsch 2006 Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy Clin Cancer Res 12 12 3652 3656 16778092 10.1158/1078-0432.CCR-06-0261 1:CAS:528:DC%2BD28XlvVSls7k%3D This article summarizes the results of studies using clinical or biological features to predict benefit from EGFR TKIs (Pubitemid 44000246)
9. F Ciardiello G Tortora 2008 EGFR antagonists in cancer treatment N Engl J Med 358 11 1160 1174 18337605 10.1056/NEJMra0707704 1:CAS:528: DC%2BD1cXjt1ahsL4%3D (Pubitemid 351398490)
10. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EFGR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized, phase 3 study. Lancet Oncol. 2011;Epub ahead of print.
11. S Heon BY Yeap GJ Britt, et al. 2010 Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EF+GFR mutations treated with gefitinib or erlotinib Clin Cancer Res 16 23 5873 5882 21030498 10.1158/1078-0432.CCR-10-1588 1:CAS:528:DC%2BC3cXhsFamtLvE This article reviews the results of a retrospective analysis to suggest a lower risk of brain relapse in patients with EGFR-mutated NSCLC who were initially treated with gefitinib or erlotinib
12. M Sun C Behrens L Feng, et al. 2009 HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors Clin Cancer Res 15 15 4829 4837 19622585 10.1158/1078-0432.CCR-08-2921 1:CAS:528: DC%2BD1MXptl2gsLY%3D
13. H Grinberg-Rashi E Ofek M Perelman, et al. 2009 The expression of the three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain Clin Cancer Res 15 5 1755 1761 19190132 10.1158/1078-0432. CCR-08-2124 1:CAS:528:DC%2BD1MXisVWrs7k%3D
14. E Rodriguez RC Lilenbaum 2010 Small cell lung cancer: past, present, and future Curr Oncol Rep 12 5 327 334 20632219 10.1007/s11912-010-0120-5 This article looks at the evolution of SCLC treatment and reviews the standard managements that are currently available, as well as ongoing clinical studies
15. A Musolino L Ciccolallo M Panebianco, et al. 2011 Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer Cancer 117 7 1837 46 21509760 10.1002/cncr.25771
16. RD Chacon MV Costanzo 2010 Triple-negative breast cancer Breast Cancer Res 12 Suppl. 2 S3 21050424 Epub
17. H Hennecke R Yerushalmi R Woods, et al. 2010 Metastatic behavior of breast cancer subtypes J Clin Oncol 28 20 3271 3277 10.1200/JCO.2009.25.9820 This article demonstrates that breast cancer subtypes are associated with distinct pattern of metastatic spread and significant difference in survival post-relapse
18. C Arslan O Dizdar K Altundag 2010 Systemic treatment in breast-cancer patients with brain metastasis Expert Opin Pharmacother 11 7 1089 1100 20345334 10.1517/14656561003702412 1:CAS:528:DC%2BC3cXntVyqt70%3D This article reviews current experience with systemic therapies in the management of patients with BMs from breast cancer
19. YH Park MJ Park SH Ji, et al. 2009 Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients Br J Cancer 100 6 894 900 19240719 10.1038/sj.bjc.6604941 1:CAS:528:DC%2BD1MXjt1Gjsb8%3D
20. J Kuhn I Robins M Mehta, et al. 2008 Tumor sequestration of lapatinib (NABTC 04-01) Neurooncology 10 Abstr ET-05
21. NU Lin LA Carey MC Liu, et al. 2008 Phase II trial of lapatinib for brain metastases in patient swith humen epidermal growth factor receptor 2-positive breast cancer J Clin Oncol 26 12 1993 1999 18421051 10.1200/JCO.2007.12.3588 1:CAS:528:DC%2BD1cXlvFaqs7o%3D
22. NU Lin V Dierras D Paul, et al. 2009 Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin Cancer Res 15 4 1452 1459 19228746 10.1158/1078-0432.CCR-08-1080 1:CAS:528:DC%2BD1MXitVOktLo%3D
23. CE Geyer A Martin B Newstat, et al. 2007 Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data J Clin Oncol 25 Abstr 1035
24. F Boccardo B Kaufman J Baselga, et al. 2008 Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d' Utilisation (ATU) J Clin Oncol 26 Abstr 1094
25. S Sutherland S Ashley D Miles, et al. 2010 Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience Br J Cancer 102 6 995 100 20179708 10.1038/sj.bjc.6605586 1:CAS:528:DC%2BC3cXjt1ynu70%3D
26. •• Lin NU, Eierman W, Greil R, et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol. 2011;Epub ahead of print. This article describes the results of a phase 2 trial assessing the clinical activity of lapatinib and capecitabine combination in patients with BMs from breast cancer. It also expounds past and current experience with the combination in the management of this patient population as well as ongoing research to ascertain the role of lapatinib monotherapy or lapatinib plus capecitabine as chemoprevention against brain relapse from breast cancer.
27. TK Eigentler A Figl D Krex, et al. 2011 Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma Cancer 117 8 1697 1703 21472716 10.1002/cncr.25631
28. J Zakrzewski LN Geraghty AE Rose, et al. 2011 Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival Cancer 117 8 1711 1720 21472718 10.1002/cncr.25643
29. Bedikian AY, Wei C, Detry M, et al. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am J Clin Oncol. 2010;Epub ahead of print.
30. JJ Raizer WJ Hwu KS Panageas, et al. 2008 Brain and leptomeningeal metastases from cutaneous melanoma∈:survival outcomes based on clinical features Neuro Oncol 10 2 199 207 18287337 10.1215/15228517-2007-058
31. •• Long GV, Kefford RF, Carr PJA, et al. Phase I/II study of GSK2118436, a selective inhibitor of V600 mutant (MUT) BRAF kinase: evidence of activity in melanoma brain metastases (METS). Ann Oncol. 2008;21(Suppl. 8), Abstr LBA27. This abstract describes the results of a phase 1/2 trial of GSK2118436, which demonstrated the activity of this agent in melanoma BMs.
32. KA Margolin AM Di Giacomo M Maio 2008 Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy Semin Oncol 37 5 468 72 10.1053/j.seminoncol.2010.09.014 This article reviews the results of a phase 2 trial of ipilimumab, which demonstrated similar clinical activity in melanoma BMs, and ongoing and future trials of combined cytotoxic and immunomodulatory therapy by US and Italian multicenter trial groups
33. •• Verma J, Jonasch E, Allen P, Tannir N, Mahajan A. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer. 2011;Epub ahead of print. This article reviews the results of a large retrospective study which demonstrated that treatment with small-molecule TKIs reduced the incidence of BMs. The study also identified that lung metastasis is a risk factor for BM development.
34. ME Gore S Hariharan C Porta, et al. 2011 Sunitinib in metastatic renal cell carcinoma patients with brain metastases Cancer 117 3 501 509 20862748 10.1002/cncr.25452 1:CAS:528:DC%2BC3MXitFKitL8%3D
35. C Massard J Zonierek M Gross-Goupil K Fizaki C Szczylik B Escudier 2010 Incidence of brain metastases in renal cell carcinoma treated with sorafenib Ann Oncol 21 5 1027 1031 19850637 10.1093/annonc/mdp411 1:STN:280: DC%2BC3c3ptFymtg%3D%3D